Can-Fite BioPharma (CANF) Change in Receivables (2013)
Can-Fite BioPharma (CANF) posted Change in Receivables of $5000.0 for Q3 2013.
Powered by 
Analysis
Can-Fite BioPharma (CANF) Change in Receivables (2013) Analysis & Trends
Can-Fite BioPharma (CANF) has 1 years of Change in Receivables data on file, last reported at $5000.0 in Q3 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.12 Bn | 628.36 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 445.86 Bn | 439.29 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 362.13 Bn | 354.99 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 268.88 Bn | 261.19 Bn | 11.24 Bn | - |
| 5 | Pfizer | 156.96 Bn | 145.26 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.26 Bn | 44.88 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 42.98 Bn | 42.98 Bn | - | - |
| 8 | Incyte | 25.13 Bn | 20.59 Bn | 1.57 Bn | 73.80 Mn |
| 9 | United Therapeutics | 21.56 Bn | 18.90 Bn | 683.80 Mn | -1.70 Mn |
| 10 | Can-Fite BioPharma | 1.80 Mn | -1.19 Mn | - | - |